Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. (Q49886940)

23 February 2018

title

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. (English)

1 reference

23 February 2018

0 references

1 reference

Shinu John

1

1 reference

23 February 2018

Olga Yuzhakov

2

1 reference

23 February 2018

Angela Woods

3

1 reference

23 February 2018

Jessica Deterling

4

1 reference

23 February 2018

Kimberly Hassett

5

1 reference

23 February 2018

Christine A Shaw

6

1 reference

23 February 2018

Giuseppe Ciaramella

7

1 reference

23 February 2018

language of work or name

English

0 references

publication date

14 February 2018

1 reference

23 February 2018

published in

Vaccine

1 reference

23 February 2018

The March towards a Vaccine for Congenital CMV: Rationale and Models

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Cytomegalovirus infections in solid organ transplantation: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

7 January 2021

mRNA transcript therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Modified mRNA Vaccines Protect against Zika Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

mRNA-based therapeutics--developing a new class of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

High epitope expression levels increase competition between T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

T cells compete for access to antigen-bearing antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Cytomegalovirus Vaccines: Current Status and Future Prospects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2018.01.029

1 reference

23 February 2018

1 reference

23 February 2018